Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech, Inc. (KRYS)
:KRYS
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.3Last Year’s EPS
0.53Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: -21.94%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements such as strong revenue growth, European expansion, and a robust clinical pipeline. However, challenges like the slowdown in reimbursement approvals and unpredictable patient pausing patterns were also discussed. The company's strong financial position and operational execution suggest a positive outlook, despite some operational challenges.Company Guidance
In the Krystal Biotech First Quarter 2025 Earnings Call, the company provided several key metrics and guidance for the upcoming periods. Net revenue for VYJUVEK in Q1 2025 was reported at $88.2 million, indicating a significant 95% growth compared to the prior year. The gross margin remained consistent at 94%, while research and development expenses rose to $14.3 million, reflecting increased personnel and clinical development costs. The company maintained a strong cash position with $765.3 million in total cash and investments. Looking forward, Krystal Biotech plans to launch VYJUVEK in Germany and France in Q3 2025, with expectations to capture a 60% market share in two years, despite a temporary slowdown in the U.S. The company anticipates regulatory approval in Japan by Q3 2025 and aims to start treating patients by Q4 2025. Additionally, Krystal Biotech is advancing its clinical pipeline with upcoming readouts in CF, AATD, aesthetics, and ocular conditions later this year, which are expected to contribute to its long-term growth strategy.VYJUVEK Revenue Growth
Net VYJUVEK revenue for the first quarter was $88.2 million, a 95% increase from the prior year.
European Expansion
Krystal Biotech received full approval for VYJUVEK in Europe with plans to launch in Germany and France in Q3 2025.
Consistent High Gross Margin
Gross margin remained strong at 94% for Q1 2025.
U.S. Patient Access
Reimbursement approvals for VYJUVEK in the U.S. exceeded 540, with full nationwide commercial and Medicaid coverage.
Strong Financial Position
Krystal Biotech ended Q1 with $765.3 million in total cash plus investments.
Clinical Pipeline Progress
Upcoming clinical readouts for CF, AATD, aesthetic skin conditions, and ocular lesions are expected later in 2025.
KRYS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KRYS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $162.29 | $139.47 | -14.06% |
Feb 19, 2025 | $156.69 | $176.17 | +12.43% |
Nov 04, 2024 | $176.39 | $170.85 | -3.14% |
Aug 05, 2024 | $191.94 | $180.71 | -5.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Krystal Biotech, Inc. (KRYS) report earnings?
Krystal Biotech, Inc. (KRYS) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Krystal Biotech, Inc. (KRYS) earnings time?
Krystal Biotech, Inc. (KRYS) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KRYS EPS forecast?
KRYS EPS forecast for the fiscal quarter 2025 (Q2) is 1.3.